Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors

LESSONS LEARNED. Treatment with BEZ235 has not been shown to demonstrate increased efficacy compared with everolimus and may be associated with a poorer tolerability profile. The hypothesis of dual targeting of the phosphatidylinositol 3‐kinase and mammalian target of rapamycin pathways in patients...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Salazar, Ramon, Garcia‐Carbonero, Rocio, Libutti, Steven K., Hendifar, Andrew E., Custodio, Ana, Guimbaud, Rosine, Lombard‐Bohas, Catherine, Ricci, Sergio, Klümpen, Heinz‐Josef, Capdevila, Jaume, Reed, Nicholas, Walenkamp, Annemiek, Grande, Enrique, Safina, Sufiya, Meyer, Tim, Kong, Oliver, Salomon, Herve, Tavorath, Ranjana, Yao, James C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2017
Soggetti:
Clinical Trial Results
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058330/
https://ncbi.nlm.nih.gov/pubmed/29242283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0144
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi